ATE364050T1 - Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen - Google Patents

Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen

Info

Publication number
ATE364050T1
ATE364050T1 AT04779112T AT04779112T ATE364050T1 AT E364050 T1 ATE364050 T1 AT E364050T1 AT 04779112 T AT04779112 T AT 04779112T AT 04779112 T AT04779112 T AT 04779112T AT E364050 T1 ATE364050 T1 AT E364050T1
Authority
AT
Austria
Prior art keywords
tweak receptor
multimeric
compositions
soluble fragments
methods concerning
Prior art date
Application number
AT04779112T
Other languages
English (en)
Inventor
Steven Wiley
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE364050T1 publication Critical patent/ATE364050T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04779112T 2003-07-24 2004-07-23 Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen ATE364050T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49003603P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
ATE364050T1 true ATE364050T1 (de) 2007-06-15

Family

ID=34102961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779112T ATE364050T1 (de) 2003-07-24 2004-07-23 Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen

Country Status (9)

Country Link
US (1) US7482430B2 (de)
EP (1) EP1648936B1 (de)
JP (1) JP4823060B2 (de)
AT (1) ATE364050T1 (de)
AU (1) AU2004259355B2 (de)
CA (1) CA2531526C (de)
DE (1) DE602004006871T2 (de)
ES (1) ES2287773T3 (de)
WO (1) WO2005010045A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
CN101160323A (zh) * 2005-04-15 2008-04-09 拉帕波特家族医学科学研究所 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
MEP35408A (en) * 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2545938A1 (de) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutische Verwendung von Anti-TWEAK-Rezeptorantikörpern
CA2729351C (en) * 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
BR112015029953A2 (pt) * 2013-06-14 2017-09-26 Bayer Pharma AG anticorpos anti-tweakr e seus usos
EP3678699A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
CA2280231A1 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
AU7549498A (en) 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
EP1021542B1 (de) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
EP1080194A2 (de) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Humane transmembranproteine
EP1100869A4 (de) 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 menschliche sekretierte proteine
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
EP2298333A3 (de) * 1999-12-20 2012-05-02 Immunex Corporation Tweak Rezeptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background

Also Published As

Publication number Publication date
WO2005010045A1 (en) 2005-02-03
ES2287773T3 (es) 2007-12-16
US20050054047A1 (en) 2005-03-10
JP4823060B2 (ja) 2011-11-24
CA2531526A1 (en) 2005-02-03
AU2004259355B2 (en) 2011-02-03
AU2004259355A1 (en) 2005-02-03
DE602004006871D1 (de) 2007-07-19
EP1648936A1 (de) 2006-04-26
JP2007527224A (ja) 2007-09-27
US7482430B2 (en) 2009-01-27
CA2531526C (en) 2012-08-21
EP1648936B1 (de) 2007-06-06
DE602004006871T2 (de) 2008-02-07

Similar Documents

Publication Publication Date Title
ATE364050T1 (de) Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
NZ754051A (en) Novel antibodies and uses thereof
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
EA201500530A1 (ru) 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
EA011572B9 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1114075T1 (el) Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
WO2005042575A3 (en) Method for down-regulation of vegf
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
EA201291346A1 (ru) Полиморфы osi-906
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
MY153719A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60135158D1 (de) Antagonisten des ige-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties